

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 June 2023 (01.06.2023)



(10) International Publication Number
WO 2023/097276 A1

(51) International Patent Classification:

A61K 31/222 (2006.01) A61P 25/16 (2006.01)
A61K 31/215 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2022/080429

(22) International Filing Date:

23 November 2022 (23.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/283,140 24 November 2021 (24.11.2021) US
63/416,745 17 October 2022 (17.10.2022) US

(71) Applicant: MAPLIGHT THERAPEUTICS, INC.
[US/US]; 501 2nd Street, San Francisco, California 94107 (US).

(72) Inventors: LILLIE, James; c/o MapLight Therapeutics, Inc., 501 2nd Street, San Francisco, California 94107 (US).
WOOD, Michael; c/o MapLight Therapeutics, Inc., 501 2nd Street, San Francisco, California 94107 (US).


(74) Agent: TUSCAN, Michael et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: METHODS OF TREATING NEUROLOGICAL DISORDERS

Figure 2



(57) Abstract: Methods of treating a neurological disorder (such as levodopa induced dyskinesia) by administering a combination of Compound 1 and fesoterodine.

[Continued on next page]

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*